References
Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in Stage III melanoma. N Engl J Med. 2020;383:1139–48.
Eggermont AM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643–54.
Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301–9.
Hieken TJ, Price DL, Piltin MA, et al. Surgeon assessment of the technical impact of neoadjuvant systemic therapy on operable stage III melanoma. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-11112-9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Tina Hieken - Research funding supporting to my institution supporting this work from Genentech. Unrelated research funding from SkylineDX. Matthew Block - Institutional research support for the project leading to the manuscript was provided by Genentech; Institutional research support from Merck and Bristol-Myers Squibb.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hieken, T.J., Piltin, M.A. & Block, M.S. ASO Author Reflections: Adding Value to Multidisciplinary Care by Incorporating Structured Surgeon Survey Assessment of the Effect of Neoadjuvant Therapies on Melanoma Operations. Ann Surg Oncol 29, 787–788 (2022). https://doi.org/10.1245/s10434-021-11117-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-11117-4